Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal clues to mysterious MSA disorder

NCT ID NCT01136213

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the brain chemical serotonin works in people with multiple system atrophy (MSA), a rare and serious nerve disease. Researchers used special PET scans to measure serotonin receptors in the brains of 53 adults with MSA or Parkinson's disease. The goal was to learn more about what causes MSA symptoms, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

53 people

The number who actually took part.

Started

Apr 2010

Finished

Mar 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with Multiple system atrophy (MSA) * MSA possible or probable * Male and female * Age : 30 to 80 * No cognitive impairment * Unmodified treatment for 2 months * Able to give informed consent * Affiliated to social insurance * Patients with idiopathic Parkinson's disease (IPD): * Positive clinical criteria for IPD * Male and female * Age : 30 to 80 * No cognitive impairment * Unmodified treatment for 2 months * Able to give informed consent * Affiliated to social insurance * Healthy controls: * Absence of neuropsychiatric disorder * Male and female * Age : 30 to 80 * Able to give informed consent * Affiliated to social insurance Exclusion Criteria: * Patients with Multiple system atrophy (MSA) * Other Parkinsonian syndrome * Dementia * Recent intake (\< 4 weeks or 8 weeks for fluoxetine) of medication acting on 5-HT1a receptors * History of major depression * Contraindication to brain MRI * Contraindication to PET * Patients with idiopathic Parkinson's disease * Other Parkinsonian syndrome * Dementia * Recent intake (\< 4 weeks or 8 weeks for fluoxetine) of medication acting on 5-HT1a receptors * History of major depression * Contraindication to brain MRI * Contraindication to PET * Healthy controls: * Patient having a neuropsychiatric disease * Recent intake (\< 4 weeks or 8 weeks for fluoxetine) of medication acting on 5-HT1a receptors * History of major depression * Contraindication to brain MRI * Contraindication to PET

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple system atrophy Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple system atrophy

Contacts and locations

Locations

  • CHU Limoges

    Limoges, France

  • CHU de Bordeaux

    Bordeaux, 33076, France

  • CHU de Toulouse

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.